Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2017

01-01-2017

Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait

Authors: Anwar Al-Awadhi, Adekunle Adekile, Rajaa Marouf

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2017

Login to get access

Abstract

Sickle cell disease (SCD) is a severe form of hemolytic anemia characterized by chronic hemolysis and is associated with increased thrombotic risk. Elevated von Willebrand factor (vWF) levels in SCD have been attributed to increased secretion and impaired processing by its cleaving protease ADAMTS-13. In this study we measured vWF and ADAMTS-13 antigen and activity levels in our SCD patients. Hematological and biochemical parameters for 59 SCD patients (20 children and 39 adults) were analyzed and compared to 59 age- and sex-matched controls. Commercially available ELISA kits were used to measure vWF and ADAMTS-13 antigen and activity levels in patients and controls. Patients had significantly higher levels of vWF (p < 0.006) and ADAMTS-13 activity (p < 0.006) compared to controls. When patients were analyzed according to age and genotype, adult patients (23 SS and 16 Sβ0thal) maintained higher vWF antigen levels (p < 0.001), but with reduced ADAMTS-13 activity to vWF:Ag ratio (p < 0.003) compared to controls. Pediatric patients (8 SS and 12 Sβ0thal) had comparable vWF antigen levels to controls (p > 0.05), but had higher levels of ADAMTS-13 activity (p < 0.011) and ADAMTS-13 activity to vWF:Ag ratio (p < 0.038). Age is an important factor to consider when vWF and ADAMTS-13 proteins are analyzed among our patients. Increased vWF in adult patients may be attributed to increased production and resistance of vWF to proteolysis rather than ADAMTS-13 deficiency. This outcome was not seen in pediatric patients as higher ADAMTS-13 activity maintained vWF antigen at comparable levels to normal controls.
Literature
1.
go back to reference Ingram VM (1957) Gene mutation in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Science 180(4581):326–328 Ingram VM (1957) Gene mutation in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Science 180(4581):326–328
2.
go back to reference Kual DK, Fabry ME, Nagel L (1989) Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci USA 86(9):3356–3360CrossRef Kual DK, Fabry ME, Nagel L (1989) Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci USA 86(9):3356–3360CrossRef
3.
go back to reference Harmening DM (2009) Clinical hematology and fundamentals of hemostasis, 5th edn. Davis Company, Philadelphia Harmening DM (2009) Clinical hematology and fundamentals of hemostasis, 5th edn. Davis Company, Philadelphia
4.
go back to reference Marouf R, D’souza TM, Adekile AD (2002) Hemoglobin electrophoresis and hemoglobinopathies in Kuwait. Med Princ Pract 11(1):38–41CrossRefPubMed Marouf R, D’souza TM, Adekile AD (2002) Hemoglobin electrophoresis and hemoglobinopathies in Kuwait. Med Princ Pract 11(1):38–41CrossRefPubMed
5.
go back to reference Adekile AD, Gu LH, Baysal E, Haider MZ, al-Fuzae L, Aboobacker KC, al-Rashied A, Huisman TH (1994) Molecular characterization of alpha-thalassemia determinants, beta-thalassemia alleles, and beta S haplotypes among Kuwaiti Arabs. Acta Haematol 92(4):176–181CrossRefPubMed Adekile AD, Gu LH, Baysal E, Haider MZ, al-Fuzae L, Aboobacker KC, al-Rashied A, Huisman TH (1994) Molecular characterization of alpha-thalassemia determinants, beta-thalassemia alleles, and beta S haplotypes among Kuwaiti Arabs. Acta Haematol 92(4):176–181CrossRefPubMed
6.
go back to reference Adekile AD, Haider MZ (1996) Morbidity, beta S haplotype and alpha-globin gene patterns among sickle cell anemia patients in Kuwait. Acta Haematol 96(3):150–154CrossRefPubMed Adekile AD, Haider MZ (1996) Morbidity, beta S haplotype and alpha-globin gene patterns among sickle cell anemia patients in Kuwait. Acta Haematol 96(3):150–154CrossRefPubMed
7.
go back to reference Akar NA, Adekile A (2008) Ten-year review of hospital admissions among children with sickle cell disease in Kuwait. Med Princ Pract 17(5):404–408CrossRefPubMed Akar NA, Adekile A (2008) Ten-year review of hospital admissions among children with sickle cell disease in Kuwait. Med Princ Pract 17(5):404–408CrossRefPubMed
8.
go back to reference Pakbaz Z, Wun T (2014) Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. Hematol Oncol Clin North Am 28(2):355–374CrossRefPubMedPubMedCentral Pakbaz Z, Wun T (2014) Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. Hematol Oncol Clin North Am 28(2):355–374CrossRefPubMedPubMedCentral
9.
go back to reference De Franceschi L, Cappellini MD, Olivieri O (2011) Thrombosis and sickle cell disease. Semin Thromb Hemost 37(3):226–236CrossRefPubMed De Franceschi L, Cappellini MD, Olivieri O (2011) Thrombosis and sickle cell disease. Semin Thromb Hemost 37(3):226–236CrossRefPubMed
10.
go back to reference Pallister C (1998) Blood: physiology and pathophysiology. Butterworth-Heinemann, Oxford Pallister C (1998) Blood: physiology and pathophysiology. Butterworth-Heinemann, Oxford
11.
go back to reference Kaul DK, Nagel RL, Chen D et al (1993) Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and for vasoocclusion. Blood 81:2429–2438PubMed Kaul DK, Nagel RL, Chen D et al (1993) Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and for vasoocclusion. Blood 81:2429–2438PubMed
12.
go back to reference Frenette PS (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9:101–106CrossRefPubMed Frenette PS (2002) Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 9:101–106CrossRefPubMed
13.
go back to reference Chen J, Hobbs WE, Le J et al (2011) The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in plasma. Blood 117:3680–3683CrossRefPubMedPubMedCentral Chen J, Hobbs WE, Le J et al (2011) The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in plasma. Blood 117:3680–3683CrossRefPubMedPubMedCentral
14.
go back to reference Kremer Hovinga JA, Studt JD, Lammle B (2003) The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiol Haemost Thromb 33:417–421CrossRefPubMed Kremer Hovinga JA, Studt JD, Lammle B (2003) The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiol Haemost Thromb 33:417–421CrossRefPubMed
15.
go back to reference Zheng X, Chung D, Takayama TK et al (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063CrossRefPubMed Zheng X, Chung D, Takayama TK et al (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063CrossRefPubMed
16.
go back to reference Novelli EM, Kato GJ, Hildesheim ME, Barge S, Meyer MP, Lozier J, Hassett AC, Ragni MV, Isenberg JS, Gladwin MT (2013) Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica 98(11):e132–e134CrossRefPubMedPubMedCentral Novelli EM, Kato GJ, Hildesheim ME, Barge S, Meyer MP, Lozier J, Hassett AC, Ragni MV, Isenberg JS, Gladwin MT (2013) Thrombospondin-1 inhibits ADAMTS13 activity in sickle cell disease. Haematologica 98(11):e132–e134CrossRefPubMedPubMedCentral
17.
go back to reference Hamed AA, Darwish YW, El-Sayed MH (2015) ADAMTS13 levels in young patients with β-thalassemia major: relation to hepatitis C virus infection, liver cirrhosis, and iron overload. Clin Appl Thromb Hemost 21(6):527–532CrossRefPubMed Hamed AA, Darwish YW, El-Sayed MH (2015) ADAMTS13 levels in young patients with β-thalassemia major: relation to hepatitis C virus infection, liver cirrhosis, and iron overload. Clin Appl Thromb Hemost 21(6):527–532CrossRefPubMed
18.
go back to reference Schnog JJ, Kremer Hovinga JA, Krieg S et al (2006) ADAMTS13 activity in sickle cell disease. Am J Hematol 81:492–498CrossRefPubMed Schnog JJ, Kremer Hovinga JA, Krieg S et al (2006) ADAMTS13 activity in sickle cell disease. Am J Hematol 81:492–498CrossRefPubMed
19.
go back to reference Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98:2730–2735CrossRefPubMed Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98:2730–2735CrossRefPubMed
20.
go back to reference Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, Ten Cate H, Reitsma PH, Wuillemin WA, Lämmle (2007) ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 5:2284–2290CrossRefPubMed Kremer Hovinga JA, Zeerleder S, Kessler P, Romani de Wit T, van Mourik JA, Hack CE, Ten Cate H, Reitsma PH, Wuillemin WA, Lämmle (2007) ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 5:2284–2290CrossRefPubMed
21.
go back to reference Al-Awadhi AM, Jadaon MM, Al-Jafar HA, Al-Wazzan HJ (2011) ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait. Acta Haematol 125(3):160–166CrossRefPubMed Al-Awadhi AM, Jadaon MM, Al-Jafar HA, Al-Wazzan HJ (2011) ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait. Acta Haematol 125(3):160–166CrossRefPubMed
22.
go back to reference Zhou Z, Han H, Cruz MA, López JA, Dong JF, Guchhait P (2009) Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 101(6):1070–1077PubMed Zhou Z, Han H, Cruz MA, López JA, Dong JF, Guchhait P (2009) Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease. Thromb Haemost 101(6):1070–1077PubMed
23.
go back to reference Chen J, Fu X, Wang Y, Ling M, McMullen B, Kulman J, Chung DW, López JA (2010) Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood 115(3):706–712CrossRefPubMedPubMedCentral Chen J, Fu X, Wang Y, Ling M, McMullen B, Kulman J, Chung DW, López JA (2010) Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13. Blood 115(3):706–712CrossRefPubMedPubMedCentral
24.
go back to reference Lippi G, Franchini M, Montagnana M, Guidi GC (2007) Coagulation testing in pediatric patients: the young are not just miniature adults. Semin Thromb Hemost 33(8):816–820CrossRefPubMed Lippi G, Franchini M, Montagnana M, Guidi GC (2007) Coagulation testing in pediatric patients: the young are not just miniature adults. Semin Thromb Hemost 33(8):816–820CrossRefPubMed
25.
go back to reference Andrew M, Mitchell L, Vegh P, Ofosu F (1994) Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 72(6):836–842PubMed Andrew M, Mitchell L, Vegh P, Ofosu F (1994) Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 72(6):836–842PubMed
26.
go back to reference Flanders MM, Phansalkar AR, Crist RA, Roberts WL, Rodgers GM (2006) Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr 149(2):275–277CrossRefPubMed Flanders MM, Phansalkar AR, Crist RA, Roberts WL, Rodgers GM (2006) Pediatric reference intervals for uncommon bleeding and thrombotic disorders. J Pediatr 149(2):275–277CrossRefPubMed
27.
go back to reference Parmar N, Albisetti M, Berry LR, Chan AK (2006) The fibrinolytic system in newborns and children. Clin Lab 52(3–4):115–24PubMed Parmar N, Albisetti M, Berry LR, Chan AK (2006) The fibrinolytic system in newborns and children. Clin Lab 52(3–4):115–24PubMed
28.
go back to reference Colombatti R, De Bon E, Bertomoro A, Casonato A, Pontara E, Omenetto E, Saggiorato G, Steffan A, Damian T, Cella G, Teso S, Manara R, Rampazzo P, Meneghetti G, Basso G, Sartori MT, Sainati L (2013) Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One 8(10):e78801CrossRefPubMedPubMedCentral Colombatti R, De Bon E, Bertomoro A, Casonato A, Pontara E, Omenetto E, Saggiorato G, Steffan A, Damian T, Cella G, Teso S, Manara R, Rampazzo P, Meneghetti G, Basso G, Sartori MT, Sainati L (2013) Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One 8(10):e78801CrossRefPubMedPubMedCentral
29.
go back to reference Favaloro EJ, Franchini M, Lippi G (2014) Aging hemostasis: changes to laboratory markers of hemostasis as we age—a narrative review. Semin Thromb Hemost 40(6):621–633CrossRefPubMed Favaloro EJ, Franchini M, Lippi G (2014) Aging hemostasis: changes to laboratory markers of hemostasis as we age—a narrative review. Semin Thromb Hemost 40(6):621–633CrossRefPubMed
30.
go back to reference Gupta R, Adekile AD (2004) MRI follow up and natural history of avascular necrosis of the femoral head in Kuwaiti children with sickle cell disease. Am J Ped Hem/Oncol 26(6):351–353CrossRef Gupta R, Adekile AD (2004) MRI follow up and natural history of avascular necrosis of the femoral head in Kuwaiti children with sickle cell disease. Am J Ped Hem/Oncol 26(6):351–353CrossRef
31.
go back to reference Adekile AD, Yacoub F, Gupta, R, Sinan, T, Al-Bloushi M, Haider MZ, Habib Y, Moosa A (2002) Silent brain infarcts are rare in Kuwaiti children with sickle cell disease and elevated Hb F. Am J Hematol 70(3):228–231CrossRefPubMed Adekile AD, Yacoub F, Gupta, R, Sinan, T, Al-Bloushi M, Haider MZ, Habib Y, Moosa A (2002) Silent brain infarcts are rare in Kuwaiti children with sickle cell disease and elevated Hb F. Am J Hematol 70(3):228–231CrossRefPubMed
32.
go back to reference Marouf R, Gupta R, Haider MZ, Adekile AD (2003) Silent brain infarcts in adult Kuwaiti sickle cell disease patients. Am J Hematol 73(4):240–243CrossRefPubMed Marouf R, Gupta R, Haider MZ, Adekile AD (2003) Silent brain infarcts in adult Kuwaiti sickle cell disease patients. Am J Hematol 73(4):240–243CrossRefPubMed
33.
go back to reference Asbeutah A, Adekile AD, Al-Sharida S, Mullah-Ali A, Mustafa NY (2014) Transcranial doppler and brain mri in sickle cell disease children with high hemoglobin F. Pediatr Blood Cancer 61(1):25–28CrossRefPubMed Asbeutah A, Adekile AD, Al-Sharida S, Mullah-Ali A, Mustafa NY (2014) Transcranial doppler and brain mri in sickle cell disease children with high hemoglobin F. Pediatr Blood Cancer 61(1):25–28CrossRefPubMed
34.
go back to reference Adekile AD, Al-Kandari M, Haider M, Marouf R, D’Souza M, Sukumaran J (2007) Hemoglobin F concentration as a function of age in Kuwaiti sickle cell patients. Med Princ Pract 16(4):286–290CrossRefPubMed Adekile AD, Al-Kandari M, Haider M, Marouf R, D’Souza M, Sukumaran J (2007) Hemoglobin F concentration as a function of age in Kuwaiti sickle cell patients. Med Princ Pract 16(4):286–290CrossRefPubMed
35.
go back to reference Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W (1985) Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 37:89–101PubMedPubMedCentral Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W (1985) Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 37:89–101PubMedPubMedCentral
36.
go back to reference Jenkis PV, O’Donnell JS (2006) ABO blood group determines plasma von Willebrand factor levels: a biologic function after all. Transfusion 46:1836–1844CrossRef Jenkis PV, O’Donnell JS (2006) ABO blood group determines plasma von Willebrand factor levels: a biologic function after all. Transfusion 46:1836–1844CrossRef
37.
go back to reference Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37(11):2672–2677CrossRefPubMed Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37(11):2672–2677CrossRefPubMed
38.
go back to reference Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR (2007). ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109(5):1998–2000CrossRefPubMed Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR (2007). ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 109(5):1998–2000CrossRefPubMed
Metadata
Title
Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait
Authors
Anwar Al-Awadhi
Adekunle Adekile
Rajaa Marouf
Publication date
01-01-2017
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2017
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-016-1418-4

Other articles of this Issue 1/2017

Journal of Thrombosis and Thrombolysis 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.